MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage.

Publication

MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage.

Journal Paper/Review - Jan 7, 2022

Schwarz Ghil, Banerjee Gargi, Hostettler Isabel, Ambler Gareth, Seiffge David J, Ozkan Hatice, Browning Simone, Simister Robert J, Wilson Duncan, Cohen Hannah, Yousry Tarek A, Al-Shahi Salman Rustam, Lip Gregory Y H, Brown Martin M, Muir Keith, Houlden Henry, Jäger Rolf, Werring David J

Citation

Schwarz G, Banerjee G, Hostettler I, Ambler G, Seiffge D, Ozkan H, Browning S, Simister R, Wilson D, Cohen H, Yousry T, Al-Shahi Salman R, Lip G, Brown M, Muir K, Houlden H, Jäger R, Werring D. MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage. Int J Stroke 2022; 18:85-94.

Type

Journal Paper/Review (English)

Journal

Int J Stroke 2022; 18

Publication Date

Jan 7, 2022

Issn Electronic

1747-4949

Pages

85-94

Brief description/objective

Cerebral amyloid angiopathy (CAA), a common cause of intracerebral hemorrhage (ICH), is diagnosed using the Boston criteria including magnetic resonance imaging (MRI) biomarkers (cerebral microbleeds (CMBs) and cortical superficial siderosis (cSS). The simplified Edinburgh criteria include computed tomography (CT) biomarkers (subarachnoid extension (SAE) and finger-like projections (FLPs)). The underlying mechanisms and diagnostic accuracy of CT compared to MRI biomarkers of CAA are unknown.